LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 157

Search options

  1. Article ; Online: Bamlanivimab Treatment Leads to Rapid Selection of Immune Escape Variant Carrying the E484K Mutation in a B.1.1.7-Infected and Immunosuppressed Patient.

    Lohr, Benedikt / Niemann, Dirk / Verheyen, Jens

    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

    2021  Volume 73, Issue 11, Page(s) 2144–2145

    MeSH term(s) Antibodies, Monoclonal, Humanized/therapeutic use ; Antibodies, Neutralizing ; Humans ; Mutation ; SARS-CoV-2
    Chemical Substances Antibodies, Monoclonal, Humanized ; Antibodies, Neutralizing ; bamlanivimab (45I6OFJ8QH)
    Language English
    Publishing date 2021-05-19
    Publishing country United States
    Document type Letter ; Comment
    ZDB-ID 1099781-7
    ISSN 1537-6591 ; 1058-4838
    ISSN (online) 1537-6591
    ISSN 1058-4838
    DOI 10.1093/cid/ciab392
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  2. Article ; Online: Dual role of signaling pathways in myeloma requires cell-type specific targeting of ligand-receptor interactions.

    Hernandez-Lopez, Pablo / Vijaykumar, Tushara / Anand, Praveen / Auclair, Daniel / Frede, Julia / Knoechel, Birgit / Lohr, Jens G

    Blood advances

    2024  

    Abstract: Although most patients with multiple myeloma respond to treatment initially, therapy resistance develops almost invariably and only a subset of patients show durable responses to immunomodulatory (IMiD) therapies. While the immune microenvironment has ... ...

    Abstract Although most patients with multiple myeloma respond to treatment initially, therapy resistance develops almost invariably and only a subset of patients show durable responses to immunomodulatory (IMiD) therapies. While the immune microenvironment has been extensively studied in myeloma patients, its composition is currently not used as prognostic markers in clinical routine. We hypothesized that the outcome of immune signaling pathway engagement can be highly variable, depending on which two cellular populations participate in this interaction. This would have important prognostic and therapeutic implications, suggesting that it is crucial for immune pathways to be targeted in a specific cellular context. To test this hypothesis, we investigated a cohort of 27 patients with newly diagnosed multiple myeloma. We examined the complex regulatory networks within the immune compartment and their impact on disease progression. Analysis of immune cell composition and expression profiles revealed significant differences in the B cell compartment associated with treatment response. Transcriptional states in patients with short time to progression demonstrated an enrichment of pathways promoting B cell differentiation and inflammatory responses, which may indicate immune dysfunction. Importantly, the analysis of molecular interactions within the immune microenvironment highlights the dual role of signaling pathways, which can either be associated with good or poor prognosis depending on the cell types involved. Our findings therefore argue that therapeutic strategies targeting ligand-receptor interactions should take into consideration the composition of the microenvironment and the specific cell types involved in molecular interactions.
    Language English
    Publishing date 2024-04-11
    Publishing country United States
    Document type Journal Article
    ZDB-ID 2915908-8
    ISSN 2473-9537 ; 2473-9529
    ISSN (online) 2473-9537
    ISSN 2473-9529
    DOI 10.1182/bloodadvances.2023011463
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  3. Article ; Online: Autoimmune basal ganglia encephalitis with hemolytic anemia.

    Werner, Ralph / Lohr, Benedikt / Lodemann, Peter / Chemnitz, Jens Marcus / Woehrle, Johannes C

    Annals of hematology

    2022  Volume 101, Issue 8, Page(s) 1857–1858

    MeSH term(s) Anemia, Hemolytic ; Anemia, Hemolytic, Autoimmune/complications ; Basal Ganglia/diagnostic imaging ; Encephalitis/complications ; Hashimoto Disease/complications ; Humans
    Language English
    Publishing date 2022-04-21
    Publishing country Germany
    Document type Case Reports ; Letter
    ZDB-ID 1064950-5
    ISSN 1432-0584 ; 0939-5555 ; 0945-8077
    ISSN (online) 1432-0584
    ISSN 0939-5555 ; 0945-8077
    DOI 10.1007/s00277-022-04848-1
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  4. Book ; Online ; Thesis: Privatisierung von Sicherheit in Deutschland, Polen und Russland

    Reifenröther, Jens Verfasser] / [Ettrich, Frank [Gutachter] / Lohr, Karin [Gutachter]

    eine komparative Analyse

    2021  

    Author's details Jens Reifenröther ; Gutachter: Frank Ettrich, Karin Lohr
    Keywords Soziale Probleme, Sozialarbeit ; Social problems, Social work
    Subject code sg360
    Language German
    Publisher Universität Erfurt
    Publishing place Erfurt
    Document type Book ; Online ; Thesis
    Database Digital theses on the web

    More links

    Kategorien

  5. Article ; Online: Tracking myeloma tumor DNA in peripheral blood.

    Waldschmidt, Johannes M / Vijaykumar, Tushara / Knoechel, Birgit / Lohr, Jens G

    Best practice & research. Clinical haematology

    2020  Volume 33, Issue 1, Page(s) 101146

    Abstract: Over the past years, the emergence of liquid biopsy technologies has dramatically expanded our ability to assess multiple myeloma without the need for invasive sampling. Interrogation of cell-free DNA from the peripheral blood recapitulates the ... ...

    Abstract Over the past years, the emergence of liquid biopsy technologies has dramatically expanded our ability to assess multiple myeloma without the need for invasive sampling. Interrogation of cell-free DNA from the peripheral blood recapitulates the mutational landscape at excellent concordance with matching bone marrow aspirates. It can quantify disease burden and identify previously undetected resistance mechanisms which may inform clinical management in real-time. The convenience of sample acquisition and storage provides strong procedural benefits over currently available testing. Further investigations will have to define the role of cell-free DNA as a diagnostic measure by determining clinically relevant tumor thresholds in comparison to existing routine parameters. This review presents an overview of currently available assays and discusses the clinical value, potential and limitations of cell-free DNA technologies for the assessment of this challenging disease.
    MeSH term(s) Antineoplastic Agents/therapeutic use ; Biomarkers, Tumor/blood ; Biomarkers, Tumor/genetics ; Circulating Tumor DNA/blood ; Circulating Tumor DNA/genetics ; GTP Phosphohydrolases/blood ; GTP Phosphohydrolases/genetics ; Gene Expression Profiling ; Genome, Human ; High-Throughput Nucleotide Sequencing/methods ; Humans ; Liquid Biopsy/methods ; Membrane Proteins/blood ; Membrane Proteins/genetics ; Multiple Myeloma/diagnosis ; Multiple Myeloma/drug therapy ; Multiple Myeloma/genetics ; Multiple Myeloma/pathology ; Mutation ; Neoplasm, Residual ; Plasma Cells/drug effects ; Plasma Cells/metabolism ; Plasma Cells/pathology ; Proto-Oncogene Proteins B-raf/blood ; Proto-Oncogene Proteins B-raf/genetics ; Proto-Oncogene Proteins p21(ras)/blood ; Proto-Oncogene Proteins p21(ras)/genetics ; Recurrence ; Tumor Suppressor Protein p53/blood ; Tumor Suppressor Protein p53/genetics
    Chemical Substances Antineoplastic Agents ; Biomarkers, Tumor ; Circulating Tumor DNA ; KRAS protein, human ; Membrane Proteins ; TP53 protein, human ; Tumor Suppressor Protein p53 ; BRAF protein, human (EC 2.7.11.1) ; Proto-Oncogene Proteins B-raf (EC 2.7.11.1) ; GTP Phosphohydrolases (EC 3.6.1.-) ; NRAS protein, human (EC 3.6.1.-) ; Proto-Oncogene Proteins p21(ras) (EC 3.6.5.2)
    Language English
    Publishing date 2020-01-14
    Publishing country Netherlands
    Document type Journal Article ; Research Support, N.I.H., Extramural ; Research Support, Non-U.S. Gov't ; Review
    ZDB-ID 2048027-1
    ISSN 1532-1924 ; 1521-6926
    ISSN (online) 1532-1924
    ISSN 1521-6926
    DOI 10.1016/j.beha.2020.101146
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  6. Article ; Online: Effects of a peripherally acting µ-opioid receptor antagonist for the prevention of recurrent acute pancreatitis: study protocol for an investigator-initiated, randomized, placebo-controlled, double-blind clinical trial (PAMORA-RAP trial).

    Cook, Mathias E / Knoph, Cecilie S / Fjelsted, Camilla A / Frøkjær, Jens B / Bilgrau, Anders E / Novovic, Srdan / Jørgensen, Maiken Thyregod / Mortensen, Michael B / Nielsen, Liv B J / Hadi, Amer / Berner-Hansen, Mark / Rutkowski, Wiktor / Vujasinovic, Miroslav / Löhr, Matthias / Drewes, Asbjørn M / Olesen, Søren S

    Trials

    2023  Volume 24, Issue 1, Page(s) 301

    Abstract: Background: Acute and chronic pancreatitis constitute a continuum of inflammatory disease of the pancreas with an increasing incidence in most high-income countries. A subset of patients with a history of pancreatitis suffer from recurrence of acute ... ...

    Abstract Background: Acute and chronic pancreatitis constitute a continuum of inflammatory disease of the pancreas with an increasing incidence in most high-income countries. A subset of patients with a history of pancreatitis suffer from recurrence of acute pancreatitis attacks, which accelerate disease progression towards end-stage chronic pancreatitis with loss of exocrine and endocrine function. There is currently no available prophylactic treatment for recurrent acute pancreatitis apart from removing risk factors, which is not always possible. Pain is the primary symptom of acute pancreatitis, which induces the endogenous release of opioids. This may further be potentiated by opioid administration for pain management. Increased exposure to opioids leads to potentially harmful effects on the gastrointestinal tract, including, e.g. increased sphincter tones and decreased fluid secretion, which may impair pancreatic ductal clearance and elevate the risk for new pancreatitis attacks and accelerate disease progression. Peripherally acting µ-opioid receptor antagonists (PAMORAs) have been developed to counteract the adverse effects of opioids on the gastrointestinal tract. We hypothesize that the PAMORA naldemedine will reduce the risk of new pancreatitis attacks in patients with recurrent acute pancreatitis and hence decelerate disease progression.
    Methods: The study is a double-blind, randomized controlled trial with allocation of patients to either 0.2 mg naldemedine daily or matching placebo for 12 months. A total of 120 outpatients will be enrolled from five specialist centres in Denmark and Sweden. The main inclusion criteria is a history of recurrent acute pancreatitis (minimum of two confirmed pancreatitis attacks). The primary endpoint is time to acute pancreatitis recurrence after randomization. Secondary outcomes include changes in quality of life, gastrointestinal symptom scores, new-onset diabetes, exocrine pancreatic insufficiency, disease severity, health care utilization, adherence to treatment, and frequency of adverse events. Exploratory outcomes are included for mechanistic linkage and include the progression of chronic pancreatitis-related findings on magnetic resonance imaging (MRI) and changes in circulating blood markers of inflammation and fibrosis.
    Discussion: This study investigates if naldemedine can change the natural course of pancreatitis in patients with recurrent acute pancreatitis and improve patient outcomes.
    Trial registration: EudraCT no. 2021-000069-34.
    Clinicaltrials: gov NCT04966559. Registered on July 8, 2021.
    MeSH term(s) Humans ; Narcotic Antagonists/adverse effects ; Quality of Life ; Acute Disease ; Analgesics, Opioid/adverse effects ; Pancreatitis, Chronic/drug therapy ; Disease Progression ; Treatment Outcome ; Double-Blind Method ; Randomized Controlled Trials as Topic
    Chemical Substances Narcotic Antagonists ; Analgesics, Opioid
    Language English
    Publishing date 2023-05-01
    Publishing country England
    Document type Clinical Trial Protocol ; Journal Article
    ZDB-ID 2040523-6
    ISSN 1745-6215 ; 1468-6694 ; 1745-6215
    ISSN (online) 1745-6215
    ISSN 1468-6694 ; 1745-6215
    DOI 10.1186/s13063-023-07287-z
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  7. Conference proceedings: Ergebnisse einer Evaluationsstudie – führt eine neue Versorgungsform für Menschen ohne Lautsprache zur Reduktion von Versorgungsdefiziten und zu besseren Outcomes?

    Zinkevich, Anna / Uthoff, Sarah A. K. / Bernasconi, Tobias / Sachse, Stefanie K. / Boenisch, Jens / Schnack, Helge / Löhr, Ann-Kathrin / Ansmann, Lena

    2021  , Page(s) 21dkvf340

    Event/congress 20. Deutscher Kongress für Versorgungsforschung (DKVF); sine loco [digital]; Deutsches Netzwerk Versorgungsforschung; 2021
    Keywords Medizin, Gesundheit
    Publishing date 2021-09-27
    Publisher German Medical Science GMS Publishing House; Düsseldorf
    Document type Conference proceedings
    DOI 10.3205/21dkvf340
    Database German Medical Science

    More links

    Kategorien

  8. Conference proceedings: Neue Versorgungsform für Menschen ohne Lautsprache – partizipative Interviewstudie mit Betroffenen im Rahmen einer Evaluation

    Uthoff, Sarah A. K. / Zinkevich, Anna / Bernasconi, Tobias / Sachse, Stefanie K. / Boenisch, Jens / Schnack, Helge / Löhr, Ann-Kathrin / Ansmann, Lena

    2021  , Page(s) 21dkvf185

    Event/congress 20. Deutscher Kongress für Versorgungsforschung (DKVF); sine loco [digital]; Deutsches Netzwerk Versorgungsforschung; 2021
    Keywords Medizin, Gesundheit
    Publishing date 2021-09-27
    Publisher German Medical Science GMS Publishing House; Düsseldorf
    Document type Conference proceedings
    DOI 10.3205/21dkvf185
    Database German Medical Science

    More links

    Kategorien

  9. Article ; Online: Surface guidance compared with ultrasound-based monitoring and diaphragm position in cone-beam computed tomography during abdominal stereotactic radiotherapy in breath-hold.

    Kaestner, Lena / Streb, Lara / Hetjens, Svetlana / Buergy, Daniel / Sihono, Dwi S K / Fleckenstein, Jens / Kalisch, Iris / Eckl, Miriam / Giordano, Frank A / Lohr, Frank / Stieler, Florian / Boda-Heggemann, Judit

    Physics and imaging in radiation oncology

    2023  Volume 27, Page(s) 100455

    Abstract: Background and purpose: Spirometry induced deep-inspiration-breath-hold (DIBH) reduces intrafractional motion during upper abdominal stereotactic body radiotherapy (SBRT). The aim of this prospective study was to evaluate whether surface scanning (SGRT) ...

    Abstract Background and purpose: Spirometry induced deep-inspiration-breath-hold (DIBH) reduces intrafractional motion during upper abdominal stereotactic body radiotherapy (SBRT). The aim of this prospective study was to evaluate whether surface scanning (SGRT) is an adequate surrogate for monitoring residual internal motion during DIBH. Residual motion detected by SGRT was compared with experimental 4D-ultrasound (US) and an internal motion detection benchmark (diaphragm-dome-position in kV cone-beam computed tomography (CBCT) projections).
    Materials and methods: Intrafractional monitoring was performed with SGRT and US in 460 DIBHs of 12 patients. Residual motion detected by all modalities (SGRT (anterior-posterior (AP)), US (AP, craniocaudal (CC)) and CBCT (CC)) was analyzed. Agreement analysis included Wilcoxon signed rank test, Maloney and Rastogi's test, Pearson's correlation coefficient (PCC) and interclass correlation coefficient (ICC).
    Results: Interquartile range was 0.7 mm (US(AP)), 0.8 mm (US(CC)), 0.9 mm (SGRT) and 0.8 mm (CBCT). SGRT(AP) vs. CBCT(CC) and US(CC) vs. CBCT(CC) showed comparable agreement (PCCs 0.53 and 0.52, ICCs 0.51 and 0.49) with slightly higher precision of CBCT(CC). Most agreement was observed for SGRT(AP) vs. US(AP) with largest PCC (0.61) and ICC (0.60), least agreement for SGRT(AP) vs. US(CC) with smallest PCC (0.44) and ICC (0.42).
    Conclusions: Residual motion detected during spirometry induced DIBH is small. SGRT alone is no sufficient surrogate for residual internal motion in all patients as some high velocity motion could not be detected. Observed patient-specific residual errors may require individualized PTV-margins.
    Language English
    Publishing date 2023-06-05
    Publishing country Netherlands
    Document type Journal Article
    ISSN 2405-6316
    ISSN (online) 2405-6316
    DOI 10.1016/j.phro.2023.100455
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

  10. Article: Motion Management in a Patient With Tracheostomy During Lung Stereotactic Body Radiation Therapy: Breath Hold Is Worth a Try.

    Kaestner, Lena / Abo-Madyan, Yasser / Huber, Lena / Spaniol, Manon / Siebenlist, Kerstin / Sacks, Marie-Kristin / Ehmann, Michael / Stieler, Florian / Clausen, Sven / Lohr, Frank / Fleckenstein, Jens / Boda-Heggemann, Judit

    Advances in radiation oncology

    2022  Volume 7, Issue 3, Page(s) 100895

    Language English
    Publishing date 2022-01-15
    Publishing country United States
    Document type Case Reports
    ISSN 2452-1094
    ISSN 2452-1094
    DOI 10.1016/j.adro.2022.100895
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

To top